Glyxambi
Glyxambi is an originator product from Boehringer Ingelheim (Schweiz) GmbH and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 95.95 to CHF 252.30 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Boehringer Ingelheim (Schweiz) GmbH
- ATC code
- A10BD19
- IT group
- 07.06.20 Orale blutzuckersenkende Mittel
- Active substances
- Empagliflozinum, Linagliptinum
- Preparation type
- Originator product
- On the SL since
- 01/03/2018
- Last price change
- 01/12/2023
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Filmtabl 10mg/5mg | Blist 30 Stk | CHF 73.14 | CHF 95.95 | 01/03/2018 | B | 7680661320018 |
| Filmtabl 10mg/5mg | Blist 90 Stk | CHF 216.89 | CHF 252.30 | 01/03/2018 | B | 7680661320025 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
- anstelle von Empagliflozin, wenn die Blutzuckerkontrolle durch Diät, Bewegung und eine Behandlung mit Empagliflozin und Metformin oder mit Empagliflozin und einem Sulfonylharnstoff unzureichend ist.
- anstelle von Linagliptin, wenn die Blutzuckerkontrolle durch Diät, Bewegung und eine Behandlung mit Linagliptin und Metformin oder mit Linagliptin und einem Sulfonylharnstoff unzureichend ist.
Als Ersatz der freien Kombination von Empagliflozin und Linagliptin bei erwachsenen Patienten mit Diabetes mellitus Typ 2, welche bereits mit dieser Kombination behandelt werden.
FAQ
Is Glyxambi covered by Swiss health insurance?
Yes, but only under conditions. Glyxambi is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Glyxambi cost in Switzerland?
The public price is the maximum price set by the FOPH and for Glyxambi ranges from CHF 95.95 to CHF 252.30 per pack. The ex-factory price ranges from CHF 73.14 to CHF 216.89. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages